Brano Therapeutics, a biotech startup aiming to translate advanced research into clinical impact for cardiovascular and metabolic diseases, has successfully closed a $6.8M seed funding round. The fresh capital marks a significant step for the company as it pushes forward with developing new therapies in these critical health areas.
The investment underscores the ongoing drive to bring scientific breakthroughs from the lab to patient care, specifically targeting conditions that affect millions globally. Brano Therapeutics was founded with the explicit goal of addressing these widespread diseases through innovative therapeutic approaches.
.png&w=3840&q=75)
